Form 4: ANAB Director Sells Shares After Option Exercise

AnaptysBio Director Magda Marquet exercised stock options and subsequently sold a portion of her common stock holdings.

Summary

• Magda Marquet, a Director of AnaptysBio, Inc. (ANAB), reported transactions on January 15, 2026.
• Exercised 11,000 stock options at an exercise price of $26.11 per share.
• Subsequently sold 9,290 shares of common stock at a weighted average price of $48.1162 per share, with prices ranging from $47.595 to $48.54.
• Also sold an additional 1,710 shares of common stock at a weighted average price of $48.849 per share, with prices ranging from $48.625 to $48.88.
• Following these transactions, Magda Marquet beneficially owns 9,930 shares of common stock directly.
• The transactions were made pursuant to a Rule 10b5-1(c) plan.
• The reporting person also holds additional options to purchase up to an aggregate of 70,104 shares of common stock, which vest according to their terms.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can sometimes be viewed with caution, this transaction appears to be a routine exercise of vested options and subsequent sale, likely for diversification or liquidity, especially given the disclosure of a Rule 10b5-1 plan. The director still holds a significant number of additional options.

Positives

• The director realized a significant profit from exercising options at $26.11 and selling shares at an average of approximately $48.12 $48.85.
• The transactions were made pursuant to a Rule 10b5-1 plan, indicating pre-planned sales and not necessarily a reaction to new, non-public information.

Negatives

• Insider selling, even if pre-planned, can sometimes be perceived by the market as a lack of confidence, though this is a common event for directors to monetize vested options.
• A reduction in direct beneficial ownership of common stock by a director.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

Insider transactions, such as option exercises and subsequent share sales, are common events in the biotechnology and pharmaceutical industries. They often reflect personal financial planning, diversification, or liquidity needs rather than a direct commentary on the company's immediate prospects, especially when conducted under a Rule 10b5-1 plan.

Stakeholder Impact

• Shareholders: The sale of shares by a director could be interpreted in various ways, from routine financial planning to a signal about future performance, potentially influencing short-term investor sentiment. However, the 10b5-1 plan mitigates concerns about opportunistic selling.

Key Dates

Keywords

AnaptysBio, ANAB, Insider Trading, Form 4, Stock Option Exercise, Share Sale, Director Transaction, Equity Sales, Rule 10b5-1